Asian Journal of Chemistry and Pharmaceutical Sciences

Open Access Open Access  Restricted Access Subscription Access

Biological Potential and Chemical Properties of Pyridine and Piperidine Fused Pyridazine Compounds: Pyridopyridazine a Versatile Nucleus


Affiliations
  • GRD (PG) IMT, Department of Pharmacy, Dehradun, India
 

Pyridopyridazine compounds are important nitrogen atom containing heterocyclic compounds due to their pharmacological versatility. This heterocycle system characterized a structural feature for different types of bioactive compounds that exhibiting various types of biological activities which make it an attractive scaffold for the design and development of new drug molecules. This article provided information about the pharmacological properties of pyridopyridazines derivatives.

Keywords

Pharmacological Properties, Pyridopyridazine, Pyridopyridazinone
User
Notifications
Font Size

  • Sainsbury M. Heterocyclic chemistry, basic concepts in chemistry. Bristol: Wiley Interscience and Royal Society of Chemistry; 2002.

  • Taniguchi T, Ogasawara K. A diastereo controlled synthesis of (+)-febrifugine: A potent antimalarial piperidine alkaloid. Organic Letters. 2000; 2(20):3193–5.

  • Takeuchi Y, Azuma K, Takakura K, Abe H, Harayama T. Asymmetric synthesis of febrifugine and isofebrifugine using yeast reduction. Chemical Commun. 2000; 17:1643–4.

  • El-Subbagh HI, Abu-Zaid SM, Mahran MA, Badria FA, Al-Obaid AM. Synthesis and biological evaluation of certain 𝛼,-unsaturated ketones and their corresponding fused pyridines as antiviral and cytotoxic agents. J Med Chem. 2000; 43(15):2915–21.

  • Perumal RV, Adiraj M, Pandiyan PS. Synthesis, analgesic and anti inflammatory evaluation of substituted 4-piperidones. Indian Drugs. 2001; 38(3):156–9.

  • Katritzky AR, Fan W-Q. A novel and versatile synthesis of 1-alkyl-, 1-aryl-, 1-(alkylamino)-, or 1-amido-substituted and of 1,2,6-trisubstituted piperidines from glutaraldehyde and primary amines or monosubstituted hydrazines. The J Org Chem. 1990; 55(10):3205–9.

  • Aridoss G, Amirthaganesan S, Ashok Kumar N, et al. A facile synthesis, antibacterial, and antitubercular studies of some piperidin-4-one and tetrahydropyridine derivatives. Bioorg and Med Chem Lett. 2008; 18(24):6542–8.

  • Margaretha VM, Armin H, Ivonne JL, et al. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)- 2H-phthalazin-1-ones and analogues. J Med Chem. 2001; 44(16):2511–22.

  • Eicher T, Hauptmann S. The Chemistry of Heterocycles: Structure, reactions, syntheses, and applications. 2nd ed. Wiley-VCH; 2003.

  • Asif M, Singh A, Lakshmayya. The development of structurally different new antitubercular molecules containing pyridazine ring system. Chronicle of Young Scientist. 2013; 4(1):1–8.

  • Asif M, Anita Singh A, Siddiqui AA. The effect of pyridazine compounds on the cardio-vascular system. Med Chem Res. 2012; 21:3336–46.

  • Asif M, Singh A, Ratnakar L. Antimicrobial Agents: Brief study of pyridazine Derivatives against some phathogenic microrganisms. J Pharm Res. 2011; 4(3):664–7.

  • Asif M, Singh A. Exploring potential, synthetic methods and general chemistry of pyridazine and pyridazinone: A brief introduction. Inter J Chem Tech and Res. 2010; 2(2):1112–28.

  • Asif M. Antifeedant, herbicidal and molluscicidal activities of pyridazinone compounds. Mini Rev in Org Chem. 2013; 10(2):113–22.

  • Asif M. The study of pyridazine compounds on prostanoids: Inhibitors of COX, cAMP phosphodiesterase, and TXA2 Synthase. J Chem. 2014. Available from: http://dx. doi.org/10.1155/2014/703238

  • Abubshait SA. An efficient synthesis and reactions of novel indolylpyridazinone derivatives with expected biological activity. Molecules. 2007; 12(1):25–42.

  • Youssef ASA, Marzouk MI, Madkour HMF, El-Soll AMA, El-Hashash MA. Synthesis of some heterocyclic systems of anticipated biological activities via 6-aryl-4-pyrazol-1-ylpyridazin- 3-one. Canadian J Chem. 2005; 83(3): 251–9.

  • Cherng S-C, Huang W-H, Shiau C-Y, Lee A-R, Chou T-C. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative. Eur J Pharmacol. 2006; 532(1-2):32–7.

  • Dogruer DS, Onkol T, Ozkan S, Ozgen S, Sahin MF. Synthesis and antimicrobial activity of some 3(2H)-pyridazinone and 1(2H)-phthalazinone derivatives. Turkish J Chem. 2008; 32(4):469–79.

  • Taleb HA. Design and synthesis of novel tetrahydro- 2HPyrano[3,2-c]Pyridazin-3(6H)-one derivatives as potential anticancer agents. Eur J Med Chem. 2010; 45(12):5724–31.

  • Ibrahim MA, Elmenoufy AH, Elagawany M, Ghoneim, MM, Moawad A. “Pyridopyridazine”: A Versatile Nucleus in Pharmaceutical Field. J Biosci and Med, 2015; 3:59–66.

  • Brown DJ. 10. Halogenophthalazines (H 178; E 514). Cinnolines and Phthalazines. The Chemistry of Heterocyclic Compounds Series. Hoboken, NJ: John Wiley and Sons, Inc; 2005. p. 203.

  • Hoffmann J, Thien, T, van’Laar A. Effects of intravenous endralazine in essential hypertension. British J Clin Pharmacol. 1983; 16:39–44.

  • Meredith PA, Elliott H, McSharry DR, Kelman AW, Reid JL. The pharmacokinetics of endralazine in essential hypertensives and in normotensive subjects. British J Clin Pharmacol. 1983; 16:27–32.

  • Carling WR, Castro PJL, Mitchinson A, Street LJ. Pyrido- pyridazine derivatives as ligands for gaba receptors. Pyrido-pyridazine derivatives as ligands for gaba receptors. Google Patents; 2001.

  • Gore PM, Looker BE, Procopiou PA, Vile S. Phthalazine and pyrido[3, 4-D]pyridazine compounds as H1 receptor antagonists. Google Patents; 2008.

  • Pettus LH, Tasker A, Wu B. Pyrido[3,2-d]pyridazine- 2(1H)-one compounds as p38 modulators and methods of use thereof. Google Patents; 2013.

  • Tynebor RM, Chen M-H, Natarajan SR, O’Neill EA, Thompson JE, Fitzgerald CE, et al. Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1. Bioorg and Med Chem Lett. 2011; 21:411–6.

  • Pakulska W, Malinowski, Z Szczesniak, AK, Czarnecka E, Epsztajn J. Synthesis and pharmacological evaluation of N-(Dimethylamino)ethyl derivatives of benzo- and pyridopyridazinones. Archiv der Pharmazie. 2009; 342:41–7.

  • Kaizerman J, Lucas B, Mcminn DL, Zamboni R. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling. Google Patents; 2010.

  • Whilhelm R, Loe B, Alvarez R, Devens B, Fong A. pyrido-[ 2,3-d]pyridazinones as potent and selective type IV phosphodiesterase inhibitors. 8th RSC-SCI Medicinal Chemistry Symposium; Cambridge, UK. 1995. p. 32.

  • Mylari BL, Zembrowski WJ, Beyer TA, Aldinger CE, Siegel TW. Orally active aldose reductase inhibitors: Indazoleacetic, oxopyridazineacetic, and oxopyridopyridazineacetic acid derivatives. J Med Chem, 1992; 35:2155–62.

  • Stanasiuk J. Investigation on the synthesis and properties of 2-(alkyl, aryl)-1,4,5-trioxo-1,2,3,4,5,6-hexahydropyrido[ 3,4-d]pyridazine, derivatives with potential biological activity. Acta Pol Pharm. 2005; 63:420–1.

  • Elassar A-ZA. Synthesis and antimicrobial activity of new polyfunctionally substituted pyridines and their fused derivatives. Indian J Chem. 2004; 43:1314–9.

  • Matyus P. 3(2H)-pyridazinones: Some recent aspects of synthetic and medicinal chemistry. J Heterocycl Chem. 1998; 35:1075–89.

  • Tynebor RM, Chen M-H, Natarajan SR, O’Neill EA, Thompson JE, Fitzgerald CE, et al. Synthesis and biological activity of pyridopyridazin-6-One p38α MAP kinase inhibitors. Part 2. Bioorg and Med Chem Lett. 2012; 22:5979–83.

  • Bishnoi M, Premkumar LS. Changes in TRP channels expression in painful conditions. The Open Pain J. 2013; 6:10–22.

  • Śladowska H, Stanasiuk J, Sieklucka-Dziuba M, Saran T, Kleinrok Z. Investigations on the synthesis and properties of 4-aminosubstituted 2,6,7-trimethyl-1,5-dioxo-1,2,5,6- tetrahydropyrido[3,4-d]pyridazines. Il Farmaco. 1998; 53:475–9.

  • Epsztajn J, Czarnecka E, Szczesniak A, Pakulska W, Malinowski Z. Benzo- and pyrido-pyridazinones with analgesic and anti inflammatory activity. Google Patents; 2009.

  • Nishikawa K, Shimkawa H, Inada Y, Shibouta Y, Kikuchi S, Yurugi S, Oka Y. Structure-activity relationships of the diuretic activity of triaza- and tetraaza-naphthalene compounds. Chem and Pharm Bull. 1976; 24:2057–77.

  • Goodacre SC, Hallett DJ. Substituted pyrido-pyridazine derivatives which enhance cognition via the GABA-A Receptors. Google Patents; 2006.

  • Mitchinson A, Blackaby WP, Bourrain S, Carling RW, Lewis RT. Synthesis of pyrido [2,3-d]pyridazines and pyrazino[ 2,3-d]-pyridazines- novel classes of GABA receptor benzodiazepine binding site ligands. Tetrahedron Lett. 2006; 47:2257–60.

  • Kurosawa M. Role of thromboxane a2 synthase inhibitors in the treatment of patients with bronchial asthma. Clin Ther. 1995; 17:2–10.

  • Dal PV, Giovannoni MP, Castellana C, Palacios JM, Beleta J, Domenech T, et al. Novel heterocyclic-fused pyridazinones as potent and selective phosphodiesterase IV inhibitors. J Med Chem. 1997; 40:1417–21.

  • Zimmet P, Alberti K, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001; 13:782–7.

  • Kakimoto S, Tonooka S. Antituberculous compounds. XXV. Some Derivatives of Pyrido [2,3-d] Pyridazine. Bull Chem Soc Japan. 1967; 40:153–9.

  • Cancer. Available: http://www.who.int/cancer/en/

  • Selvakumar P, Thennarasu S, Mandal AB. Synthesis of novel pyridopyridazin-3(2h)-one derivatives and evaluation of their cytotoxic activity against MCF-7 cells. Inter Scholarly Res Notices; 2014. Article ID: 410716.

  • Rennie RP. Current and future challenges in the development of antimicrobial agents. In: Coates, ARM, Ed. Antibiotics Resistance, Handbook of Experimental Pharmacology. Springer-Verlag, Berlin; 2012. p. 45–65.

  • Biancanali C, Giovannoni MP, Pieretti S, Cesari N, Graciano A, Vergelli C, Cilibrizzi A, di Gianuario A, Colucci M, Mangano G, Garrone B, Polenzani, L, dal Piaz V. Further studies on arylpiperazinyl alkyl pyridazinones: discovery of an exceptionally potent, orally active, antinociceptive agent in thermally induced pain. J Med Chem. 2009; 52:7397– 409.

  • Rodrguez-Ciria M, Sanz AM, Yunta MJR, Gomez-Contreras F, Navarro P, Fernandez I, Pardo M, Cano C. Synthesis and cytotoxic activity of N,N-bis-{3-[N-(4- Chlorobenzo[ g]-phthalazin-1-yl)]aminopropyl}-N-methylamine: A new potential DNA bisintercalator. Bioorg Med Chem. 2003; 11:2143–8.

  • Lee SG, Kim JJ, Kim KH, Kweon DH, Kang YJ, Cho SD, Kim SK, Yoon Y. Recent progress in pyridazin-3(2h)-ones chemistry. J Curr Org Chem. 2004; 8:1463–80.

  • Orru RVA, de Greaf M. Recent advances in solution-phase multicomponent methodology for the synthesis of heterocyclic compounds. Synthesis. 2003; 10:1471–99.

  • Butnariu R, Caprosu M, Bejan V, Ungureanu M, Poiata A, Tuchilus C, Florescu M, Mangalagiu I I. Pyridazine and Phthalazine Derivatives with 1149 Potential Antimicrobial Activity. J Het Chem. 2007; 44:1149–55.

  • Coelho A, Sotelo E, Ravina E. Pyridazine derivatives. Part 33: Sonogashira approaches in the synthesis of 5-substituted- 6-phenyl-3(2H)-pyridazinones. Tetrahedron, 2003; 59:2477–88.

  • Rathish IG, Kalim J, Shamim A, et al. Synthesis and evaluation of anticancer activity of some novel 6-aryl-2-(psulfamylphenyl)- pyridazin-3(2H)-ones. Eur J Med Chem. 2012; 49:304–9.

  • Livermone DGH, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DVS, Lamont RB, Noble SA, Orr DC, Payne JJ, Ramsay MVJ, Shingler AH, Smith AH, Storer R, Williamson C, Willson T. Synthesis and anti-HIV-1 Activity of a series of imidazo[1,5-b]pyridazines. J Med Chem. 1993; 36:3784–94.

  • Altomare C, Cellamare S, Summo L, Catto M, Carotti A. Inhibition of monoamine oxidase-b by condensed pyridazines and pyrimidines: effects of lipophilicity and structure- activity relationships. J Med Chem. 1998; 41:3812–20.

  • Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer’s disease. Bioorg Med Chem. 2013; 21:2434–50.


Abstract Views: 556

PDF Views: 235




  • Biological Potential and Chemical Properties of Pyridine and Piperidine Fused Pyridazine Compounds: Pyridopyridazine a Versatile Nucleus

Abstract Views: 556  |  PDF Views: 235

Authors

Mohammad Asif
, India

Abstract


Pyridopyridazine compounds are important nitrogen atom containing heterocyclic compounds due to their pharmacological versatility. This heterocycle system characterized a structural feature for different types of bioactive compounds that exhibiting various types of biological activities which make it an attractive scaffold for the design and development of new drug molecules. This article provided information about the pharmacological properties of pyridopyridazines derivatives.

Keywords


Pharmacological Properties, Pyridopyridazine, Pyridopyridazinone

References